Pedram Razavi, MD, PhD

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.

Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.

Key opinion leaders on breast cancer management share insight on the evolving role of antibody drug conjugates and their potential impact on care.

Following her review of TROPiCS-02, Joyce O’Shaughnessy, MD, shares data from the DESTINY-Breast04 study of T-DXd in HER2-low metastatic breast cancer.

Expert Joyce O’Shaughnessy, MD, reviews data from the TROPiCS-02 study of sacituzumab govitecan in HR+/HER2- metastatic breast cancer.

Expert perspectives on a second patient case of unmutated metastatic breast cancer and available treatment strategies in this setting.

Expert panelists consider how they might apply data from the EMERALD study in their real-world management of HR+/HER2- metastatic breast cancer.

A focused review of data from the EMERALD study, which tested elacestrant, an oral SERD, in patients with HR+/HER2- metastatic breast cancer.

In light of the second-line treatment armamentarium for patients with HR+/HER2- metastatic breast cancer, expert oncologists discuss the selection and sequencing of specific agents in this setting.

Joyce O’Shaughnessy, MD, highlights key data from a number of clinical trials in the second-line treatment setting of HR+/HER2- metastatic breast cancer.

Before closing out their module on ESR1 mutation, panelists identify its impact on treatment options for patients diagnosed with HR+/HER2- metastatic breast cancer.

In the context of ESR1 mutation in HR+/HER2- metastatic breast cancer, key opinion leaders consider ideal testing modalities and timing to improve patient outcomes.

Centering discussion on the first patient case, panelists reflect on the importance of ESR1 mutation in the setting of HR+/HER2- metastatic breast cancer.

Focused discussion on the evolving role of germline testing in HR+/HER2- metastatic breast cancer and how it may impact treatment pathways.

Key opinion leaders provide insight on testing strategies, primarily circulating tumor DNA, in patients diagnosed with HR+/HER2- metastatic breast cancer.

Opening their program on HR+/HER2- metastatic breast cancer, expert oncologists consider the growing list of therapeutic targets to test for in patients with early or late-stage disease.